Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Explore the Feasibility of AVATAMED in Predicting the Cilnical Response to Temozolomide in Glioblastoma Patients, a Single-center, Prospective Study

NCT04313842 is registered in ClinicalTrials.gov with Doo-Sik Kong as lead sponsor.

NCT NCT04313842
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04313842 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Explore the Feasibility of AVATAMED in Predicting the Cilnical Response to Temozolomide in Glioblastoma Patients, a Single-center, Prospective Study
Lead sponsor
Doo-Sik Kong
Phase
Observational
Overall status
Unknown status
Start date
July 1, 2019
Completion date
January 1, 2022
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma